Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Patients who struggle with appetite control, cravings, and overeating are often good candidates for GLP-1, particularly if theyve already tried a traditional diet and exercise without success
Tirzepatide achieved MASH resolution rates of 44% to 62% across doses in the SYNERGY-NASH trial (up to 73% on the efficacy estimand at 15 mg)
Earlier this month, Eli Lilly and Co
Kellner DA et al
JAMA , 325(14), 1416-1425
Inject subcutaneously with the knee slightly bent
US$ 25.33
US$ 27.81
US$ 21.60
